

GB04101256



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

WIPO

18 MAY 2004


PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

Dated

Andrew Gersey
27 April 2004

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

NOT AVAILABLE COPY
100%

THE PATENT OFFICE
B
20 MAR 2003
NEWPORT

The Patent Office
Cardiff Road
Newport
Gwent NP9 1RH

1. Your reference NW/7609

2. Patent application number
(The Patent Office will fill in this part)

0306394.8

20 MAR 2003

3. Full name, address and postcode of the or of
each applicant (underline all surnames)

The University of Nottingham
University Park, Nottingham, NG7 2RD,
United Kingdom.

Patents ADP number (if you know it)

7610223001

If the applicant is a corporate body, give the
country/state of its incorporation

United Kingdom

4. Title of the invention

Carnitine Retention

5. Name of your agent (if you have one)

Swindell & Pearson

"Address for service" in the United Kingdom
to which all correspondence should be sent
(including the postcode)

48 Friar Gate,
Derby DE1 1GY

Patents ADP number (if you know it)

00001578001

6. If you are declaring priority from one or more
earlier patent applications, give the country
and the date of filing of the or of each of these
earlier applications and (if you know it) the or
each application number

Country

Priority application number
(if you know it)Date of filing
(day / month / year)

7. If this application is divided or otherwise
derived from an earlier UK application,
give the number and the filing date of
the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right
to grant of a patent required in support of
this request? (Answer 'Yes' if:

YES

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body.

See note (d)

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

0

Description

13

Claim(s)

0

Abstract

0

Drawing(s)

4 + 4

PL

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)


Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination
(Patents Form 10/77)

Any other documents
(please specify)

I/We request the grant of a patent on the basis of this application.

Signature



Date 19/03/03

Swindell & Pearson

11. 12. Name and daytime telephone number of person to contact in the United Kingdom

N. Womsley - 01332 367051

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- d) If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- e) Once you have filled in the form you must remember to sign and date it.
- f) For details of the fee and ways to pay please contact the Patent Office.

Carnitine Retention

5 This invention relates to carnitine retention in biological tissue. More particularly, but not exclusively, the invention relates to compositions and methods of increasing carnitine retention in the animal and/or human body.

10 It is known that carnitine is essential in muscle metabolism function. In particular the muscle store of carnitine is important for energy production in muscle. If the store of carnitine declines, the function of the muscle can be impaired. Indeed, patients with muscle carnitine deficiency experience premature fatigue and weakness.

15 Previous studies (Harper *et al*, 1988, Segre *et al* 1988, Rebouche 1991), where oral doses of L-carnitine between 2 and 6 g were administered, demonstrate peak plasma concentrations ~3 h after ingestion and state a bioavailability of less than 20%. This poor absorptive status may be due to the fact that intestinal absorption of L-carnitine is normally near saturation (Taylor, 2001). Further studies (Rebouche *et al*, 1994, Brass *et al*, 1994) showed that if plasma carnitine concentrations exceed maximum renal reabsorption (60-100 μ mol/L), the excess is excreted in the urine with a clearance approximating the glomerular filtration rate. From these features of carnitine's pharmacokinetics, and the fact that the normal plasma carnitine concentration of 40-50 μ mol/L is sufficient to yield near maximal rates of skeletal muscle carnitine uptake (K_m 6.4 μ M in isolated cells, Georges *et al*, 2000), it can be predicted that oral L-carnitine supplementation would have little, if any, impact on skeletal muscle carnitine content or metabolism in humans (Brass, 2000).

30 A study by Vukovich *et al* (1994) showed that L-carnitine supplementation (6 g every day for up to 2 weeks) resulted in no significant increase in resting skeletal muscle carnitine content and suggested that there was already an adequate amount of carnitine within the muscle to support fatty acid oxidation

5 during exercise. However, Vukovich's study did not look at carnitine status in muscle. The results seen in a study by van Loon *et al*, 2001 which did look at carnitine status in muscle do suggest, in contradiction to Vukovich, that there is

10 5 not enough carnitine within the muscle to support fatty acid oxidation during exercise at workloads above 70% maximal oxygen consumption (VO_2 max). Other studies (Grieg *et al*, 1987, Oyono-Enguelle *et al*, 1988, Soop *et al*, 1988, Wyss *et al*, 1990, Decombaz *et al*, 1993), involved orally supplemented 3-5 g L-carnitine, in subjects with varying levels of fitness, over 5-28 days and measured

15 10 the effects on various endpoints of exercise. Findings from these studies concluded that there was no effect of L-carnitine on VO_2 max, RQ, maximal exercise, fatty acid utilisation, glucose utilisation, lactate, perceived exertion, or heart rate. However, again these studies did not measure skeletal muscle carnitine content. If skeletal muscle carnitine content did not increase then

15 15 clearly there would not be an affect on skeletal muscle metabolism and thus, an enhancement in the endpoints measured.

20 In contrast to these findings, Marconi *et al* (1985) did observe a slight but significant increase in VO_2 max in competitive walkers, after oral supplementation of 4 g L-carnitine every day for 2 weeks, which they concluded was most likely due to an increase in TCA flux as lipid metabolism did not change. Vecchiet *et al* (1990) also observed an increase in VO_2 max. However, only a single dose (2 g, orally) was supplemented an hour before exercise and, due to the features of carnitine's pharmacokinetics, it is highly unlikely the observed effects were a 25 result of an increase in skeletal muscle carnitine, which was not measured.

30 According to one aspect of the present invention there is provided a composition for influencing carnitine retention in biological tissue, the composition comprising a carnitine substance and an agent to increase sodium-potassium ATPase pump activity in the tissue.

The invention further provides a composition for influencing carnitine transport into biological tissue, the composition comprising a carnitine substance

to increase blood/plasma carnitine concentration and an agent to increase the activity of a carnitine transport protein.

5 According to a further aspect of the present invention there is provided a composition for increasing carnitine retention in the animal and/or human body, the composition comprising a carnitine substance and an agent to increase blood/plasma insulin concentration.

10 The invention also provides a method of influencing carnitine retention in biological tissue, in particular tissue of the animal and/or human body, the method comprising administering to the tissue a carnitine substance and an agent operable to increase sodium-potassium ATPase pump activity in the tissue.

15 The invention further provides a method of increasing carnitine retention in the animal and/or human body, the method comprising administering to the body a carnitine substance and an agent to increase blood/plasma insulin concentration.

20 The invention still further provides a method of influencing carnitine transport into biological tissue, the method comprising administering to the body a carnitine substance to increase blood/plasma carnitine concentration and an agent to increase the activity of a carnitine transport protein.

25 Preferably the method increases carnitine retention in the tissue by increasing the transportation of the carnitine substance, or a derivative thereof into tissue cells. Preferably transportation is increased by stimulation of a sodium dependent transport protein and substantially simultaneously increasing 30 blood/plasma carnitine concentration.

Preferably the agent is operable to increase sodium dependent carnitine uptake into tissue cells, in particular skeletal muscle, liver and/or kidney cells.

The agent may be operable to increase insulin activity in the tissue, desirably by increasing the amount of insulin in the blood/plasma. The agent may comprise carbohydrate or an active derivative thereof. Alternatively, or in 5 addition, the agent may comprise amino acid and/or protein.

Preferably the method involves oral administration and desirably ingestion of the carnitine substance and agent, desirably but not necessarily simultaneously.

10 According to a still further aspect of the present invention there is provided a food supplement comprising a carnitine substance and an agent as described in any of the preceding paragraphs.

15 The invention further provides a composition for use in the manufacture of a medicament for influencing carnitine retention in biological tissue, the composition comprising a carnitine substance and an agent to increase sodium-potassium ATPase pump activity in the tissue.

20 The invention also provides a composition for use in the manufacture of medicament for influencing carnitine transport into biological tissue, the composition comprising a carnitine substance to increase blood/plasma carnitine concentration and an agent to increase the activity of a carnitine transport protein.

25 There is also provided a composition for use in the manufacture of a medicament to influence carnitine retention in the animal and/or human body, the composition comprising a carnitine substance and an agent to stimulate insulin release and activity in the body.

30 The invention also relates to the use of a carnitine substance and an agent as described in any of the preceding paragraphs for influencing carnitine retention in human and/or animal tissue.

Carnitine is also provided for use in a method substantially as described in any of the paragraphs above.

5 A kit is provided according to this invention comprising a carnitine substance and an agent substantially as described in any of the paragraphs above.

10 According to another aspect of the present invention, there is provided a carnitine substance for use in administration to the human and/or animal body with an agent as described in any of the paragraphs above.

15 Desirably, the carnitine substance comprises one or more of carnitine, a functional equivalent of carnitine, an active derivative of carnitine or carnitine analogue. A preferred embodiment may comprise one or more of L-carnitine, a functional equivalent of L-carnitine, an active derivative of L-carnitine or an analogue thereof.

20 Preferably the agent is a carbohydrate or a derivative of a carbohydrate. The carbohydrate is preferably a simple carbohydrate, which may be a simple sugar. Conveniently, the carbohydrate comprises glucose, but other sugars can be used, for example sucrose or fructose.

25 Preferably between 10 and 150 times the amount by weight of carbohydrate is administered to one unit of carnitine substance. Preferably approximately 3 g of the carnitine substance is administered with a total of approximately 30 to 450 g of agent, the agent being administered to achieve substantially simultaneous elevation of insulin and carnitine concentrations in the blood/plasma.

30

The composition may be provided in a solution which may be an aqueous solution.

An embodiment of the invention will now be described by way of example only with reference to the accompanying drawings, in which:-

5 Fig. 1 shows serum insulin concentrations following carnitine ingestion with Control (○) and CHO (●);

Fig. 2 shows urinary total carnitine (TC), free carnitine (FC) and acylcarnitine (AC) excretion in mg over 24 hours following carnitine ingestion with Control (□) and CHO (■);

10 Fig. 3 shows plasma TC concentration measured over 7 hours following carnitine ingestion with Control (□) and CHO (■). The arrows A, B, C, D indicate time of ingestion of drink; and

15 Fig. 4 shows the area under the plasma-time curves (AUC) for total carnitine (TC), free carnitine (FC) and acylcarnitine (AC) measured over 7 hours following carnitine ingestion with Control (□) and CHO (■).

Referring to the figures, the invention provides a composition, methodology and uses of a composition to influence carnitine retention in tissue such as muscle, liver and kidney tissue in the animal and/or human body which 20 comprise a carnitine substance and an agent to increase blood/plasma insulin concentration with a view to increasing sodium-potassium ATPase pump activity in tissue, and thereby sodium dependent carnitine transport.

The carnitine substance comprises one or more of L-carnitine, a functional 25 equivalent of L-carnitine, an active derivative of L-carnitine or an analogue thereof.

The agent can be anything which acts to increase insulin concentration, including amino acids and protein. However in this embodiment the agent is a 30 carbohydrate such as a sugar, for example glucose which acts to stimulate insulin production in the body.

Eight, healthy, moderately trained, non-vegetarian men (age 22.3 ± 0.7 yr,

body mass 79.7 ± 2.5 kg, and body mass index 24.3 ± 0.9 kg/m²) were used in the following study.

5 The study protocol utilised a blind crossover design where subjects acted as their own controls. Following an overnight fast, subjects reported to the laboratory on two occasions, separated by a 2 week "wash out" period to ensure similar basal muscle carnitine concentrations among experimental treatments. On arrival, subjects voided their bladder and were asked to rest in a supine 10 position on a bed while a cannula was inserted retrogradely into a superficial vein on the dorsal surface of the non-dominant hand. This hand was kept in a hand-warming unit (air temperature 55°C) to arterialise the venous drainage of the hand and a saline drip was attached to keep the cannula patent.

15 After a basal blood sample was taken, subjects consumed 3.01 g (3 x 1.5 g L-carnitine L-tartrate effervescent tablets) L-carnitine (Lonza Group, Basel, Switzerland) dissolved in 200 ml of water. After 1 hour and then 3 more times every 1.5 hours (h), subjects consumed a 500 ml drink over a 5 min period in a randomised order containing either sugar free orange drink (Control) or 94 g of 20 simple sugars (CHO) (Original Lucozade, GlaxoSmithKline, Brentford, UK).

25 Subjects abstained from the consumption of meat, dairy produce, alcohol, and strenuous exercise 24 hours before each visit and for a 24 hour period after the consumption of the carnitine solution. It was essential that subjects had a minimal intake of carnitine in their diet during this period; therefore, food was supplied to the subjects as a ready-made meal, free from carnitine.

30 During each experimental visit, 5 ml of arterialised venous (a-v) blood were obtained every 20 min for 7 h after which subjects left the laboratory, returning for a final 24 hour blood sample. Two ml of this blood were collected into lithium heparin containers and, after centrifugation (14,000 rpm for 2 min), the plasma was removed and immediately frozen in liquid nitrogen. These samples were then stored at -80°C and analysed for free and total carnitine

concentrations at a later date. The remaining blood was allowed to clot, and, after centrifugation (3,000 rpm for 10 min), the serum was stored frozen at -20°C. ~~Insulin concentration was measured in these samples at a later date with a~~
5 radioammunoassay kit (Coat-a-Count Insulin, DPC, Ca, USA).

Urine was collected in 5 litre bottles, containing 5 ml of 10% thymol/isopropanol preservative, for 24 h following the consumption of the carnitine drink and returned to the laboratory the following morning where a final 10 blood sample was taken. The 24 h volume was recorded and 5 ml aliquots were removed and stored at -20°C to be analysed for free and total carnitine concentrations at a later date.

The method used for the determination of carnitine is based on the 15 carnitine acetyltransferase (CAT) catalysed reaction:

L-carnitine + [¹⁴C]acetyl-CoA \leftrightarrow [¹⁴C]acetyl-L-carnitine + CoASH and measures the concentration of [¹⁴C]acetyl-L-carnitine. The reaction is reversible, but the removal of CoASH via complex with N-ethylmaleimide (NEM) ensures the 20 reaction is driven quantitatively to the right and that all the L-carnitine is labelled. To separate labelled acetyl-L-carnitine from any remaining [¹⁴C]acetyl-CoA Cederblad & Lindstedt (1972) introduced the use of anion-exchange resin. The negatively charged acetyl-CoA remains in the resin whereas the positive acetyl-L-carnitine is excluded for collection.

25

L-carnitine for use in the standards was purchased from Sigma Chemical Co., St. Louis, Mo. U.S.A., as was the unlabelled acetyl-coenzyme A (sodium salt, purity 90-95%), N-ethylmaleimide, and the Dowex 1X 8 (200-400 mesh, Cl⁻ form). [¹⁴C]acetyl-coenzyme A was obtained from Amersham, Buckinghamshire, 30 UK (specific radioactivity 10 μ Ci). Carnitine acetyltransferase (5 mg/ml) was obtained from Roche Molecular Biochemicals, East Sussex, U.K. and scintillation liquid (Scintillator Plus) was purchased from Packard Biosciences, Groninger, The Netherlands.

9
All samples were analysed in duplicate. For plasma samples, 50 μ l plasma were pipetted, by positive displacement, into a 3 ml glass test tube. After the addition of 1.2 ml chloroform/methanol ($\text{CHCl}_3:\text{CH}_3\text{OH}$, 3:2) the sample was 5 vortexed, and then centrifuged at 4,500 rpm for 10 min. The supernatant was poured off to another glass tube while the pellet, after being broken up with a plastic rod, was ashed with a further 0.6 ml $\text{CHCl}_3:\text{CH}_3\text{OH}$, vortexed and centrifuged again (4,500 rpm, 10 min). This second supernatant was pooled with the first and the sample was dried by the evaporation of the $\text{CHCl}_3:\text{CH}_3\text{OH}$ under 10 N_2 .

For total carnitine, all of the acyl-carnitine bonds were hydrolysed by the addition of 100 μ l 0.1 M KOH to the test tube. The sample was then placed in a water bath at 50°C for 2 h. After incubation 20 μ l of 0.5 M HCl were added to 15 neutralised the sample.

For free carnitine, 120 μ l H_2O (Millipor) were added to make the free and total solutions of equal volume.

20 For urine samples 10 μ l urine were pipetted, by positive displacement, into a 3 ml glass test tube and diluted with 40 μ l urine were pipetted, by positive displacement, into a 3 ml glass test tube and diluted with 40 μ l H_2O (Millipor). The sample then underwent the same procedure as the plasma sample.

25 For the preparation of standards, 15, 30, 45, 60, 75, and 90 μ l of 40 $\mu\text{mol/l}$ L-carnitine standard solution were pipetted into 3.5 ml test tubes and made up to 120 μ l volume by adding H_2O (Millipor). This produced 7 standards with L-carnitine concentrations of 0, 600, 1200, 1800, 2400, 3000, and 3600 pmol/l.

30 Radioenzymatic analysis of carnitine was carried out by adding twenty-five μ l phosphate buffer (1 M, pH 6.5), 25 μ l acetyl-CoA (300 μM), 10 μ l NEM (40 mM), and 25 μ l (^{14}C]acetyl-CoA (4 μM) to each tube. Carnitine acetyltransferase

(CAT) diluted 1:10 was then defrosted and 20 μ l were added to each sample at 20 s intervals. After 30 min incubation at room temperature the contents of each tube were transferred to a column of Dowex 1X-8 contained in a Pasteur pipette

5 at 20 s intervals using an automatic pipette (Microlab 1000, Hamilton, Bonaduz, Switzerland). The pipette aspirated each 240 μ l sample with a 10 μ l air gap, mixed with 250 μ l water (Millipor) and then voided the solution into the top of column. The tube was then washed with 250 μ l water (Millipor), which were then aspirated, mixed with 250 μ l water (Millipor) and voided into the same column.

10 The effluent was collected into 20 ml vials and mixed with 10 ml scintillation fluid. β -radioactivity of each of the vials was counted for 3 min.

A two-way ANOVA (time and treatment effects, SPSS version 10, USA) was performed to detect differences in plasma carnitine and serum insulin. A 15 Student's paired *t*-test was used to locate differences in 24 h urinary carnitine content and area under plasma time curved between treatments. The total area under the plasma carnitine-time curve was calculated using KaleidaGraph (version 3.51, Synergy Software, USA). Statistical significance was declared at P < 0.05, and all the values are means \pm SE.

20

The results will now be discussed with particular reference to the drawings.

Fig. 1 shows a plot of serum insulin concentrations following carnitine 25 ingestion with Control CON (o) and carbohydrate CHO (•). Insulin concentration was significantly higher ($P<0.01$) following ingestion of four 500 ml drinks in the carbohydrate group (94 g simple sugars indicated by arrows A, B, C, D at $t = 60$, 150, 240 and 330) than in the control group (sugar free indicated by arrows $t = 60, 150, 240$ and 330). Values are \pm SE expressed in mU/l ($n = 8$).

30

Fig. 2 shows a graph of urinary total carnitine (TC), free carnitine (FC) and acylcarnitine (AC) excretion in mg over a period of 24 hours following an oral

dose of 3.01 g of L-carnitine ingestion with control (CON) and carbohydrate (CHO). Mean urinary TC, FC and AC secretion was reduced when subjects consumed CHO compared to Control, and * indicates that excretion was 5 significantly lower in the case of TC and AC ($P<0.05$). Values are means \pm SE expressed in mg/24 hr ($n = 8$).

Fig. 3 shows a plot of plasma total carnitine concentration measured over 7 hours following an oral dose of 3.01 g L-carnitine with Control (□) and 10 carbohydrate (■).

The arrows A, B, C and D indicate time of ingestion of drink. No significant differences ($P<0.05$) were seen between the two groups (Control and CHO), either at basal or at any point following ingestion. Values are means \pm SE 15 expressed in $\mu\text{mol/l}$ ($n = 8$).

Fig. 4 shows a plot of the area under the plasma-time curves (AUC) for total carnitine (TC), free carnitine (FC) and acylcarnitine (AC) measured over a 7 hour period following an oral dose of 3.01 g L-carnitine with Control (CON) and 20 carbohydrate (CHO). No significant differences were seen in TC and FC AUC's when comparing Control and carbohydrate, but AC was significantly lower ($P<0.05$) following CHO, resulting in a significant decrease in plasma carnitine concentration with CHO. Values are means \pm SE expressed in mmol/l/min ($n = 8$).

25

The results show that L-carnitine supplementation together with CHO results in a smaller loss of urinary carnitine than that seen with Control. Total (TC), free (FC) and acyl (AC) carnitine were all excreted less with CHO, than in Control.

30

From the results it can be seen that insulin, released as a result of ingesting carbohydrate (CHO), stimulates L-carnitine retention. Insulin increases carnitine retention most probably by increasing sodium-potassium ATPase pump

activity and, thus, sodium dependent transport of carnitine into cells (particularly skeletal and cardiac muscle). Insulin may also enable more FC to be available to tissues by 1) inhibiting acylation of supplemented L-carnitine and/or 2) by 5 stimulating carnitine retention by reabsorption by the kidney.

The present invention therefore has useful application in increasing carnitine retention in muscle tissue and thereby reducing the effects of depleted carnitine in muscle, including muscle fatigue and impaired muscular 10 performance.

Various modifications may be made without departing from the spirit or scope of the present invention. For example other agents may be used which stimulate carnitine retention primarily by way of increasing carnitine transport into 15 tissue, such as insulin or active derivatives thereof. Other agents may include, either as an alternative or as an addition, amino acid(s) and protein(s). Active derivatives, variants or analogues of carnitine may be used. The composition may be administered in any convenient form such as tablet, powder, pellet or the like and otherwise than by ingestion, such as injection.

20


Between 10 and 150 times the amount by weight of agent such as carbohydrate may be administered to one unit of carnitine substance.

The invention can be used to increase carnitine retention in animal as well 25 as human bodies, and in whole bodies, tissues or cells derived therefrom.

The invention also provides a kit comprising a carnitine substance and an agent such as a carbohydrate, as described above.

Whilst endeavouring in the foregoing specification to draw attention to those features of the invention believed to be of particular importance it should be understood that the Applicant claims protection in respect of any patentable feature or combination of features hereinbefore referred to and/or shown in the

drawings whether or not particular emphasis has been placed thereon.



Urinary carnitine, mg / 24 h







Fig 2





PCT/GB2004/001256



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.